SCYNEXIS INC — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
SCYNEXIS received a contract from BARDA (U.S. Department of Health and Human Services) providing up to $214 million in non-dilutive funding to develop SCY-247, a second-generation antifungal candidate, through NDA submission for two indications (treatment of invasive candidiasis and prevention of invasive fungal infections). The initial base period provides $18.5 million; the contract is structured as a cost-share arrangement and may extend up to 10 years. The company maintains its existing cash runway guidance into 2029 and states SCY-770 (lead ADPKD program) development milestones remain unchanged.
Why this rating
Contract value ($214M potential, $18.5M immediate) is 8.3× company market cap—transformational for a $25.7M company. Non-dilutive funding eliminates dilution, extends runway, enables pipeline expansion. However, contingent on option exercise and cost-share obligations; does not alter lead program trajectory.
Price action (we called it positive)
before filing · preread $4.71 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.